A detailed history of D. E. Shaw & Co., Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 2,642,020 shares of ACAD stock, worth $41.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,642,020
Previous 3,754,598 29.63%
Holding current value
$41.2 Million
Previous $118 Million 58.45%
% of portfolio
0.04%
Previous 0.11%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$17.79 - $30.86 $19.8 Million - $34.3 Million
-1,112,578 Reduced 29.63%
2,642,020 $48.9 Million
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $21.5 Million - $32.9 Million
-1,034,400 Reduced 21.6%
3,754,598 $118 Million
Q3 2023

Nov 14, 2023

SELL
$20.84 - $33.47 $9.88 Million - $15.9 Million
-474,080 Reduced 9.01%
4,788,998 $99.8 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $6.45 Million - $9.3 Million
362,496 Added 7.4%
5,263,078 $126 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $11.1 Million - $14.3 Million
681,183 Added 16.14%
4,900,582 $92.2 Million
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $7 Million - $9.18 Million
-492,781 Reduced 10.46%
4,219,399 $67.2 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $360,016 - $466,159
25,515 Added 0.54%
4,712,180 $77.1 Million
Q2 2022

Aug 15, 2022

BUY
$13.01 - $27.22 $1.82 Million - $3.8 Million
139,702 Added 3.07%
4,686,665 $66 Million
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $413,774 - $543,400
19,760 Added 0.44%
4,546,963 $110 Million
Q4 2021

Feb 14, 2022

SELL
$16.79 - $27.09 $17.5 Million - $28.3 Million
-1,043,329 Reduced 18.73%
4,527,203 $106 Million
Q3 2021

Nov 15, 2021

BUY
$15.78 - $24.77 $12.7 Million - $20 Million
805,467 Added 16.9%
5,570,532 $92.5 Million
Q2 2021

Aug 16, 2021

BUY
$19.4 - $27.42 $46.8 Million - $66.1 Million
2,409,857 Added 102.32%
4,765,065 $116 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $2.81 Million - $6.18 Million
112,408 Added 5.01%
2,355,208 $60.8 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $891,101 - $1.23 Million
-21,713 Reduced 0.96%
2,242,800 $120 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $4.24 Million - $6.63 Million
116,305 Added 5.41%
2,264,513 $93.4 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $33.7 Million - $45.2 Million
858,079 Added 66.51%
2,148,208 $104 Million
Q1 2020

May 15, 2020

SELL
$31.65 - $46.87 $2.75 Million - $4.08 Million
-86,965 Reduced 6.32%
1,290,129 $54.5 Million
Q4 2019

Feb 14, 2020

SELL
$36.21 - $51.4 $32.4 Million - $46 Million
-895,290 Reduced 39.4%
1,377,094 $58.9 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $8.23 Million - $16.3 Million
370,534 Added 19.48%
2,272,384 $81.8 Million
Q2 2019

Aug 14, 2019

BUY
$23.32 - $28.12 $10.8 Million - $13 Million
461,869 Added 32.07%
1,901,850 $50.8 Million
Q1 2019

May 15, 2019

BUY
$16.17 - $27.38 $20.9 Million - $35.3 Million
1,290,639 Added 864.22%
1,439,981 $38.7 Million
Q4 2018

Feb 14, 2019

BUY
$14.32 - $22.92 $2.14 Million - $3.42 Million
149,342 New
149,342 $2.42 Million
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $733,159 - $1.23 Million
-56,267 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$15.07 - $22.34 $570,218 - $845,300
37,838 Added 205.32%
56,267 $859,000
Q3 2017

Nov 14, 2017

BUY
$29.49 - $38.37 $543,471 - $707,120
18,429
18,429 $694,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.52B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.